| Dr Tiffany Campbell, | |
|
1650 30th St Se, Washington, DC 20020-3702 | |
| (202) 729-3250 | |
| Not Available |
| Full Name | Dr Tiffany Campbell |
|---|---|
| Gender | Female |
| Speciality | Psychologist - School |
| Location | 1650 30th St Se, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144814377 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TS0200X | Psychologist - School | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tiffany Campbell, 1200 1st St Ne Fl 9, Washington, DC 20002-7953 Ph: () - | Dr Tiffany Campbell, 1650 30th St Se, Washington, DC 20020-3702 Ph: (202) 729-3250 |
News Archive
The Royal College of Speech and Language Therapists has partnered with Wiley-Blackwell, the scientific, technical, medical and scholarly publishing business of John Wiley & Sons, Inc., to publish their journal International Journal of Language and Communication Disorders (IJLCD), starting in 2011.
Severe COVID-19 is associated with massive dysregulation of the host immune response, resulting in inflammation and the condition known as a cytokine storm. For the most part, however, the virus is barely noticeable or only mild among the young and healthy, suggesting that the route and intensity of an immune response could determine the severity of the disease.
Researchers from the University of Surrey have today launched a new programme of research called eSMART (Electronic Symptom Management using ASyMS Remote Technology), that uses mobile phone technology to remotely monitor patients who are undergoing chemotherapy to treat breast, bowel and blood cancers.
Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI- (natalizumab) were published today in a supplement to the medical journal Multiple Sclerosis.
Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck's comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.
› Verified 5 days ago
Dr. Leila Bremer, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1330 New Hampshire Ave Nw, Suite 106, Washington, DC 20036 Phone: 202-887-0404 | |
Dr. Chester Wayne Bullock Jr., PSYD, MED Psychologist Medicare: Not Enrolled in Medicare Practice Location: 910 17th St Nw Ste 419, Washington, DC 20006 Phone: 202-505-2795 | |
Dr. Megan Laabs, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 6900 Georgia Ave Nw, Washington, DC 20307 Phone: 202-782-8671 | |
Dana Footer, PSYD Psychologist Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-5000 | |
Dr. Jennifer Lee Bakalar, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2000 P St Nw Ste 408, Washington, DC 20036 Phone: 202-932-0893 | |
Dr. Karin Leah Arndt, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 4601 Connecticut Ave Nw, Suite 20, Washington, DC 20008 Phone: 716-239-0723 | |
Renee Michelle Neely-walters, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 5800 8th St Nw, Washington, DC 20011 Phone: 202-541-6608 |